The Extracellular Matrix Regulates Cancer Progression and Therapy Response: Implications for Prognosis and Treatment

被引：36

作者：

Denys, Hannelore ^{[2
]}

Braems, Geert ^{[3
]}

Lambein, Kathleen ^{[4
]}

Pauwels, Patrick ^{[4
]}

Hendrix, An ^{[2
]}

De Boeck, Astrid ^{[1
]}

Mathieu, Veronique ^{[5
]}

Bracke, Marc ^{[1
]}

De Wever, Olivier ^{[1
]}

机构：

[1] Ghent Univ Hosp, Dept Radiotherapy & Nucl Med, Lab Expt Canc Res, B-9000 Ghent, Belgium

[2] Ghent Univ Hosp, Dept Med Oncol, B-9000 Ghent, Belgium

[3] Ghent Univ Hosp, Dept Gynecol, B-9000 Ghent, Belgium

[4] Ghent Univ Hosp, Dept Pathol, B-9000 Ghent, Belgium

[5] Free Univ Brussels ULB, Inst Pharm, Toxicol Lab, Brussels, Belgium

来源：

CURRENT PHARMACEUTICAL DESIGN | 2009年 / 15卷 / 12期

关键词：

FOCAL ADHESION KINASE; CELL LUNG-CANCER; PROSTATE-SPECIFIC ANTIGEN; RESISTANCE CAM-DR; HEPARAN-SULFATE; GROWTH-FACTOR; INDUCED APOPTOSIS; BETA(1) INTEGRIN; GENE-EXPRESSION; STROMAL CELLS;

D O I：

10.2174/138161209787846711

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Emerging evidence points towards a key role of the extracellular matrix (ECM) during tumor progression and therapy resistance. Paradoxically, in today's routine of cancer management the ECM is not taken into account. It is the aim of the present review to broaden our understanding of the mechanisms of therapy resistance, taking the ECM as a presumptive central regulator. The stromal ecosystem drives the accumulation of ECM at the invasion front. Therefore, we address the question whether the detection of ECM signatures in histopathology and biofluids may help predicting therapy resistance and determining the prognosis of cancer. Since the ECM is an attractive target for tumor therapy, current therapeutic strategies in preclinical or clinical development will be discussed.

引用

页码：1373 / 1384

页数：12

共 126 条

[1] The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel [J].